Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.